Literature DB >> 12957321

The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease.

Willa A Hsueh1, Ronald Law.   

Abstract

Recent evidence suggests that progression of insulin resistance parallels progression of atherosclerosis. Fat plays an integral role in the development of type 2 diabetes and vascular injury. The balance of adipose-derived substances, including free fatty acids, tumor necrosis factor-alpha, leptin, adiponectin, and plasminogen activator inhibitor-1, determine both insulin action and the state of vascular inflammation. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands promote the balance of these substances to enhance insulin-mediated glucose uptake and decrease inflammation. PPAR-gamma ligands reverse the major defect of the insulin resistance syndrome and have important effects that inhibit atherosclerosis, improve endothelial cell function, and attenuate inflammation. Although more research is needed, data suggest that PPAR-gamma ligands may prevent the progression of insulin resistance to diabetes and endothelial dysfunction to atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957321     DOI: 10.1016/s0002-9149(03)00610-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

1.  The use of beta-adrenergic blockade in preventing trauma-induced hepatomegaly.

Authors:  Robert E Barrow; Robert R Wolfe; Mohan R Dasu; Laura N Barrow; David N Herndon
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

Review 2.  Neel revisited: the adipocyte, seasonality and type 2 diabetes.

Authors:  E M Scott; P J Grant
Journal:  Diabetologia       Date:  2006-05-17       Impact factor: 10.122

3.  Glycemia and insulinemia evaluation after high-sucrose and high-fat diets in lean and overweight/obese women.

Authors:  A C P Volp; H H M Hermsdorff; J Bressan
Journal:  J Physiol Biochem       Date:  2008-06       Impact factor: 4.158

Review 4.  Inflammatory Mechanisms of Diabetes and Its Vascular Complications.

Authors:  Lyudmila V Nedosugova; Yuliya V Markina; Leyla A Bochkareva; Irina A Kuzina; Nina A Petunina; Irina Y Yudina; Tatiana V Kirichenko
Journal:  Biomedicines       Date:  2022-05-18

5.  Down-regulation of lipoprotein lipase increases glucose uptake in L6 muscle cells.

Authors:  Veronica Lopez; Kumuda Saraff; Jheem D Medh
Journal:  Biochem Biophys Res Commun       Date:  2009-08-19       Impact factor: 3.575

6.  Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study.

Authors:  J Tamaki; M Iki; A Morita; Y Ikeda; Y Sato; E Kajita; S Kagamimori; Y Kagawa; H Yoneshima
Journal:  Osteoporos Int       Date:  2009-05-30       Impact factor: 4.507

7.  Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention.

Authors:  Takahiro Masuda; Yiling Fu; Akiko Eguchi; Jan Czogalla; Michael A Rose; Alexander Kuczkowski; Maria Gerasimova; Ariel E Feldstein; Miriam Scadeng; Volker Vallon
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-17       Impact factor: 4.310

8.  Serum concentrations of adiponectin and leptin in patients with thyroid dysfunctions.

Authors:  F Santini; A Marsili; C Mammoli; R Valeriano; G Scartabelli; C Pelosini; M Giannetti; R Centoni; P Vitti; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

Review 9.  Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.

Authors:  Bodh I Jugdutt
Journal:  Clin Interv Aging       Date:  2010-12-03       Impact factor: 4.458

10.  Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation.

Authors:  Melvin R Hayden; Suresh C Tyagi
Journal:  Nutr J       Date:  2004-05-10       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.